A new urine test to detect prostate cancer without invasive procedures
Noninvasive, Uniplex, Molecular, Pathomic Urinary Assay for Detection of Prostate Cancer
This study is working on a new, simple urine test to help tell if someone has prostate cancer and what kind it is, so patients can avoid unnecessary and uncomfortable biopsies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10899730 on NIH RePORTER |
What this research studies
This research focuses on developing a noninvasive urine assay to detect prostate cancer, aiming to reduce the need for invasive biopsies that often yield benign results. By analyzing molecular markers in urine, the study seeks to differentiate between aggressive, indolent, and benign forms of prostate cancer. The approach utilizes advanced genomic profiling techniques to improve diagnostic accuracy and patient management. This innovative method could provide a safer and more efficient way to diagnose prostate cancer, ultimately benefiting patients by minimizing unnecessary procedures.
Who could benefit from this research
Good fit: Ideal candidates for this research are men who are at risk for prostate cancer or have elevated prostate-specific antigen (PSA) levels.
Not a fit: Patients who have already been diagnosed with prostate cancer and are undergoing treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more accurate and less invasive method for diagnosing prostate cancer, reducing patient discomfort and healthcare costs.
How similar studies have performed: Previous research has shown promise in using molecular profiling for cancer detection, but this specific approach is novel and aims to improve upon existing methods.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Thakur, Mathew Laxman — Thomas Jefferson University
- Study coordinator: Thakur, Mathew Laxman
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.